Strides Pharma to Conduct Clinical Trials for Potential COVID-19 Drug in India

Bengaluru: Bengaluru-based pharmaceutical company Strides Pharma Science has obtained approval from the Drug Controller General of India to conduct clinical trials of potential coronavirus drug favipiravir.

The development comes after Glenmark Pharmaceuticals last month said it became the first pharma company in India to get the approval to conduct favipiravir trials. The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.

As many as 5,609 fresh Covid-19 cases were reported in the country in the last 24 hours, taking the total number of cases in the country to 1,12,359.
India is among 11 countries that has over a 1,00,000 cases.